We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
BLRX

Price
2.89
Stock movement up
+0.14 (5.09%)
Company name
BioLineRx Ltd
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
6.08M
Ent value
41.48M
Price/Sales
0.25
Price/Book
0.71
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-21.53%
1 year return
-89.68%
3 year return
-64.96%
5 year return
-46.57%
10 year return
-46.04%
Last updated: 2025-04-14

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

DIVIDENDS

BLRX does not pay dividends or no data was received

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales0.25
Price to Book0.71
EV to Sales1.72

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

FINANCIALS

Per share

Loading...
Per share data
Current share count2.10M
EPS (TTM)-3.37
FCF per share (TTM)-15.18

Income statement

Loading...
Income statement data
Revenue (TTM)24.05M
Gross profit (TTM)19.42M
Operating income (TTM)-20.80M
Net income (TTM)-6.73M
EPS (TTM)-3.37
EPS (1y forward)-4.40

Margins

Loading...
Margins data
Gross margin (TTM)80.75%
Operating margin (TTM)-86.52%
Profit margin (TTM)-27.99%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash8.84M
Net receivables3.96M
Total current assets37.85M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment0.00
Total assets52.74M
Accounts payable4.63M
Short/Current long term debt29.61M
Total current liabilities24.96M
Total liabilities44.24M
Shareholder's equity8.51M
Net tangible assets0.00

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-49.37M
Capital expenditures (TTM)91.00K
Free cash flow (TTM)-30.35M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-79.13%
Return on Assets-12.76%
Return on Invested Capital-35.71%
Cash Return on Invested Capital-161.05%

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open2.87
Daily high2.90
Daily low2.77
Daily Volume18K
All-time high3330.00
1y analyst estimate182.67
Beta0.87
EPS (TTM)-3.37
Dividend per share-
Ex-div date-
Next earnings date-

Downside potential

Loading...
Downside potential data
BLRXS&P500
Current price drop from All-time high-99.91%-12.04%
Highest price drop-100.00%-56.47%
Date of highest drop29 Jan 20259 Mar 2009
Avg drop from high-81.67%-11.07%
Avg time to new high1133 days12 days
Max time to new high3324 days1805 days

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
BLRX (BioLineRx Ltd) company logo
Marketcap
6.08M
Marketcap category
Small-cap
Description
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Employees
79
Investor relations
-
SEC filings
CEO
Philip Adam Serlin
Country
USA
City
Modi'in
Stock type
American depositary share
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

UNDERSTAND THE BUSINESS
Loading...